This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01197066?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
